secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269537
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%
--------------------------------------------------------------------------------

- Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.
- Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.
- Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).
- Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.
- Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/0001193125-25-269537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/alec-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer